Definium Shares Jump After 2nd Phase 3 LSD Anxiety Study Beats 4-Point Bar
Updated
Updated · Investor's Business Daily · Aug 12
Definium Shares Jump After 2nd Phase 3 LSD Anxiety Study Beats 4-Point Bar
3 articles · Updated · Investor's Business Daily · Aug 12
Summary
Definium Therapeutics unveiled a second positive Phase 3 readout for its LSD-based anxiety drug, sending the biotech stock higher on Thursday.
GAD patients improved by 5.4 points versus placebo on the 56-point Hamilton Anxiety Rating Scale, topping the roughly 4-point benefit investors had been looking for.
The result reinforces earlier late-stage data for DT120, where a single 100-microgram dose significantly reduced generalized anxiety disorder symptoms and the effect lasted 12 weeks.
With two positive Phase 3 studies now in hand, the company strengthens its case to advance the psychedelic therapy toward potential regulatory filing and commercialization.